Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx (RARE) Reports Q1 Loss, Tops Revenue Estimates
06:47pm, Tuesday, 04'th May 2021
Ultragenyx (RARE) delivered earnings and revenue surprises of -62.40% and 33.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx to Present at Truist Securities Life Sciences Summit
04:01pm, Wednesday, 28'th Apr 2021
NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se
Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
05:47pm, Tuesday, 27'th Apr 2021
NOVATO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra
Why Is Ultragenyx (RARE) Down 22% Since Last Earnings Report?
12:08pm, Saturday, 13'th Mar 2021
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx to Present at Barclays Global Healthcare Conference
08:31am, Wednesday, 03'rd Mar 2021
NOVATO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser
Ultragenyx to Present at Upcoming Investor Conferences
04:01pm, Wednesday, 17'th Feb 2021
NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
Ultragenyx's Dojolvi Ok'd In Canada For Genetic Metabolic Disorder
10:44am, Wednesday, 17'th Feb 2021
Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chai
First Approved Treatment for Adult and Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) in Canada First Approved Treatment for Adult and Pediatric Patients with Long-chain F
Ultragenyx (RARE) Q4 Loss Narrows Y/Y, Revenues Beat Estimates
11:22am, Friday, 12'th Feb 2021
Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2020 Results - Earnings Call Transcript
11:09pm, Thursday, 11'th Feb 2021
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q4 2020 Results - Earnings Call Transcript
Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
06:56pm, Thursday, 11'th Feb 2021
Ultragenyx (RARE) delivered earnings and revenue surprises of -26.42% and 28.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
04:05pm, Thursday, 11'th Feb 2021
2020 total revenue of $271.0 million and 2020 Crysvita 1 revenue to Ultragenyx of $138.9 million
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
08:31am, Thursday, 04'th Feb 2021
NOVATO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rar
Clinical trial will utilize a single-protocol Phase 1/2/3 design
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance
11:17am, Tuesday, 12'th Jan 2021
Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.
